Justin C Brown1,2, Michael O Harhay2, Meera N Harhay3. 1. Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. 2. Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania, Philadelphia, PA. 3. Division of Nephrology, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA.
Abstract
OBJECTIVE: This study seeks to quantify the relationship between anthropometrically-predicted visceral adipose tissue (apVAT) and all-cause and cause-specific mortality among individuals of European descent in a population-based prospective cohort study of 10,624 participants. METHODS: The apVAT with a validated regression equation that included age, body mass index, and waist and thigh circumferences were predicted. RESULTS: During a median of 18.8 years, 3531 participants died with 1153 and 741 deaths attributable to cardiovascular disease and cancer, respectively. In multivariable-adjusted analyses that accounted for demographic, clinical, and behavioral characteristics, higher apVAT was associated with an increased risk of all-cause (Ptrend < .001), cardiovascular-specific (Ptrend < .001), and cancer-specific mortality (Ptrend = .007). Excluding participants with a history of cancer, myocardial infarction, heart failure, or diabetes at baseline did not substantively alter effect estimates. apVAT more accurately predicted all-cause, cardiovascular-specific, and cancer-specific mortality than body mass index (P < .001), waist circumference (P < .001), or the combination of body mass index and waist circumference (P < .001). CONCLUSIONS: These data provide evidence that apVAT is associated with all-cause and cause-specific mortality in a large population-based sample of men and women of European descent. These results support the use of apVAT to risk-stratify individuals for premature mortality when imaging data are not available such as in routine clinical practice or in large clinical trials.
OBJECTIVE: This study seeks to quantify the relationship between anthropometrically-predicted visceral adipose tissue (apVAT) and all-cause and cause-specific mortality among individuals of European descent in a population-based prospective cohort study of 10,624 participants. METHODS: The apVAT with a validated regression equation that included age, body mass index, and waist and thigh circumferences were predicted. RESULTS: During a median of 18.8 years, 3531 participants died with 1153 and 741 deaths attributable to cardiovascular disease and cancer, respectively. In multivariable-adjusted analyses that accounted for demographic, clinical, and behavioral characteristics, higher apVAT was associated with an increased risk of all-cause (Ptrend < .001), cardiovascular-specific (Ptrend < .001), and cancer-specific mortality (Ptrend = .007). Excluding participants with a history of cancer, myocardial infarction, heart failure, or diabetes at baseline did not substantively alter effect estimates. apVAT more accurately predicted all-cause, cardiovascular-specific, and cancer-specific mortality than body mass index (P < .001), waist circumference (P < .001), or the combination of body mass index and waist circumference (P < .001). CONCLUSIONS: These data provide evidence that apVAT is associated with all-cause and cause-specific mortality in a large population-based sample of men and women of European descent. These results support the use of apVAT to risk-stratify individuals for premature mortality when imaging data are not available such as in routine clinical practice or in large clinical trials.
Authors: Robert Ross; Ian Janssen; Jody Dawson; Ann-Marie Kungl; Jennifer L Kuk; Suzy L Wong; Thanh-Binh Nguyen-Duy; SoJung Lee; Katherine Kilpatrick; Robert Hudson Journal: Obes Res Date: 2004-05
Authors: T Pischon; H Boeing; K Hoffmann; M Bergmann; M B Schulze; K Overvad; Y T van der Schouw; E Spencer; K G M Moons; A Tjønneland; J Halkjaer; M K Jensen; J Stegger; F Clavel-Chapelon; M-C Boutron-Ruault; V Chajes; J Linseisen; R Kaaks; A Trichopoulou; D Trichopoulos; C Bamia; S Sieri; D Palli; R Tumino; P Vineis; S Panico; P H M Peeters; A M May; H B Bueno-de-Mesquita; F J B van Duijnhoven; G Hallmans; L Weinehall; J Manjer; B Hedblad; E Lund; A Agudo; L Arriola; A Barricarte; C Navarro; C Martinez; J R Quirós; T Key; S Bingham; K T Khaw; P Boffetta; M Jenab; P Ferrari; E Riboli Journal: N Engl J Med Date: 2008-11-13 Impact factor: 91.245
Authors: Sophie V Eastwood; Therese Tillin; Andrew Wright; John Heasman; Joseph Willis; Ian F Godsland; Nita Forouhi; Peter Whincup; Alun D Hughes; Nishi Chaturvedi Journal: PLoS One Date: 2013-09-17 Impact factor: 3.240
Authors: Gabriel S Tajeu; John N Booth; Lisandro D Colantonio; Rebecca F Gottesman; George Howard; Daniel T Lackland; Emily C O'Brien; Suzanne Oparil; Joseph Ravenell; Monika M Safford; Samantha R Seals; Daichi Shimbo; Steven Shea; Tanya M Spruill; Rikki M Tanner; Paul Muntner Journal: Circulation Date: 2017-06-20 Impact factor: 29.690
Authors: Izabela Uzar; Anna Bogacz; Elżbieta Sowińska-Przepiera; Krzysztof Piątek; Filip Przerwa; Marlena Wolek; Bogusław Czerny Journal: J Clin Med Date: 2022-06-20 Impact factor: 4.964
Authors: Matej Pekař; Anna Pekařová; Marek Bužga; Pavol Holéczy; Marek Soltes Journal: Wideochir Inne Tech Maloinwazyjne Date: 2020-03-04 Impact factor: 1.195
Authors: Nitin Kapoor; Stephen A Jiwanmall; Munaf B Nandyal; Dheeraj Kattula; Sandhiya Paravathareddy; Thomas V Paul; John Furler; Brian Oldenburg; Nihal Thomas Journal: Diabetes Metab Syndr Obes Date: 2020-09-16 Impact factor: 3.168